Dendreon Corporation (DNDN), a Washington state based biotechnology company saw it’s shares plummet off a cliff a few weeks ago, after pulling the plug on it’s sales forecast for it’s flagship cancer therapy Provenge.  This was done after poor initial sales due to the high cost (in the $100k ballpark) of the therapy, and the